Optimizing MR-Guided Radiotherapy for Breast Cancer Patients

Maureen L. Groot Koerkamp*, Jeanine E. Vasmel, Nicola S. Russell, Simona F. Shaitelman, Carmel N. Anandadas, Adam Currey, Danny Vesprini, Brian M. Keller, Chiara De-Colle, Kathy Han, Lior Z. Braunstein, Faisal Mahmood, Ebbe L. Lorenzen, Marielle E.P. Philippens, Helena M. Verkooijen, Jan J.W. Lagendijk, Antonetta C. Houweling, H. J.G.Desiree van den Bongard, Anna M. Kirby, on behalf of the Breast Tumor Site Group of the International MR-Linac Atlantic Consortium

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

111 Downloads (Pure)


Current research in radiotherapy (RT) for breast cancer is evaluating neoadjuvant as opposed to adjuvant partial breast irradiation (PBI) with the aim of reducing the volume of breast tissue irradiated and therefore the risk of late treatment-related toxicity. The development of magnetic resonance (MR)–guided RT, including dedicated MR-guided RT systems [hybrid machines combining an MR scanner with a linear accelerator (MR-linac) or 60Co sources], could potentially reduce the irradiated volume even further by improving tumour visibility before and during each RT treatment. In this position paper, we discuss MR guidance in relation to each step of the breast RT planning and treatment pathway, focusing on the application of MR-guided RT to neoadjuvant PBI.

Original languageEnglish
Article number1107
JournalFrontiers in Oncology
Number of pages13
Publication statusPublished - 28. Jul 2020


  • breast cancer
  • hybrid machine
  • magnetic resonance imaging (MRI)
  • MR-guided radiotherapy
  • MR-linac
  • neoadjuvant radiation therapy
  • partial breast irradiation


Dive into the research topics of 'Optimizing MR-Guided Radiotherapy for Breast Cancer Patients'. Together they form a unique fingerprint.

Cite this